Table 1 Patient baseline characteristics (N = 385)
Patient characteristics | Patients, n (%) | |
|---|---|---|
Age, years | 65–69 | 110 (28.6) |
70–74 | 140 (36.4) | |
75–79 | 94 (24.4) | |
≥ 80 | 37 (9.6) | |
NR | 4 (1.0) | |
Gender | Male | 258 (67) |
Female | 127 (33) | |
Ethnicity | Caucasian | 382 (99.2) |
Asian | 2 (0.5) | |
Afro-American | 0 (0) | |
Other | 1 (0.3) | |
ECOG PS | 0 | 64 (16.6) |
1 | 210 (54.5) | |
2 | 92 (23.9) | |
3 | 3 (0.8) | |
NR | 16 (4.2) | |
Smoking status | Never smoked | 91 (23.7) |
Former smoker | 198 (51.4) | |
Current smoker | 77 (20.0) | |
NR | 19 (4.9) | |
Tumor histology | Adenocarcinoma | 250 (64.9) |
Squamous cell carcinoma | 86 (22.3) | |
Large cell carcinoma | 16 (4.2) | |
Bronchoalveolar carcinoma | 11 (2.9) | |
Adenoid squamous cell carcinoma | 10 (2.6) | |
Other | 12 (3.1) | |
EGFR mutation status | Tested | 119 (30.9) |
Positive | 18 (15.1) | |
Wild-type | 98 (82.4) | |
Indefinite | 3 (2.5) | |
Previous chemotherapy | Carboplatin | 279 (72.5) |
Cisplatin | 124 (32.2) | |
Docetaxel | 54 (14.0) | |
Gemcitabine | 96 (24.9) | |
Paclitaxel | 56 (14.5) | |
Vinorelbine | 92 (23.9) | |
Other | 182 (47.3) | |